Market Place
Sourcing Support
BMS skates again on $6.4B Celgene shareholder lawsuit
02 Oct 2024 //
FIERCE PHARMA
Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US
16 May 2024 //
FDA
Bristol Myers` bowel disease drug fails in late-stage study
29 Mar 2024 //
REUTERS
Health Canada Issues Recall of Celgene Inc`s ISTODAX (romidepsin) – Restricted Access Program
20 Mar 2023 //
HEALTH CANADA
Bristol Myers wins dismissal of a $6.4 billion lawsuit over cancer drug delay
02 Mar 2023 //
REUTERS
Sun Pharma gets USFDA nod to market generic medication
10 Feb 2023 //
ECONOMIC TIMES
Dr Reddy`s Lab among generic pharma companies in US to face antitrust litigation
23 Nov 2022 //
ECONOMIC TIMES
BMS scores a topline treat in Reblozyl phase 3 study
01 Nov 2022 //
FIERCEPHARMA
Celgene, Acceleron alum Backstrom tapped to lead Scholar Rock
20 Sep 2022 //
FIERCEBIOTECH
Jounce’s latest setback dampens outlook for another cancer immunotherapy target
31 Aug 2022 //
BIOPHARMADIVE
Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Approval in US
08 Jul 2022 //
FDA
Bristol must face a lawsuit filed by former Celgene shareholders
27 Jun 2022 //
FIERCEPHARMA
BMS dusts off an old Celgene chemotherapy for use in children
23 May 2022 //
ENDPTS
Celgene Must Face Humana Suit on ‘Supracompetitive’ Drug Prices
28 Apr 2022 //
BLOOMBERG LAW
BMS Announces Accepted Amounts and Pricing Terms of its Tender Offers
02 Mar 2022 //
BUSINESSWIRE
Sandoz launches generic oncology treatment in Europe
19 Feb 2022 //
PMLIVE
JPM 2022: Licensing and research tie-ups trump M&A
14 Jan 2022 //
FIERCEBIOTECH
Bristol Myers notes 3 key launches to counter Revlimid losses
11 Jan 2022 //
FIERCEPHARMA
Otezla now the only oral drug for all levels of plaque psoriasis
22 Dec 2021 //
FIERCEPHARMA
BMS doubles down on Immatics with new $770M biobucks collab
14 Dec 2021 //
FIERCEBIOTECH
BMS channels $15B for share buybacks
14 Dec 2021 //
FIERCEPHARMA
Amgen`s Otezla Shines Again in Psoriasis
03 Dec 2021 //
BIOSPACE
Bristol-Myers Sues to Block Copies of Revlimid, Its Top Seller
22 Nov 2021 //
BLOOMBERGLAW
BMS, after weighing Acceleron buy, now eyes Aurinia: Bloomberg
23 Oct 2021 //
FIERCEPHARMA
Ventyx nabs an upsized IPO to challenge BMS` Zeposia
21 Oct 2021 //
FIERCEBIOTECH
ShouTi snags $100M for oral drugs to treat chronic diseases
21 Oct 2021 //
MEDCITYNEWS
Fierce Pharma Asia—Takeda`s cell, gene therapy deals; BMS-BeiGene Abraxane brawl
15 Oct 2021 //
FIERCEPHARMA
ANP Technologies Terminates Merger Negotiations with Sorrento Therapeutics
29 Sep 2021 //
BUSINESSWIRE
Bristol Myers Squibb previews new `transform` corporate campaign
28 Sep 2021 //
FIERCEPHARMA
Mystery suitor lines up $11B Acceleron acquisition: report
27 Sep 2021 //
FIERCEBIOTECH
Oncology, RNA biotech 858 Therapeutics inks $60M series A
22 Sep 2021 //
FIERCEBIOTECH
Amgen scores Otezla patent win, nabbing protection until 2028
22 Sep 2021 //
FIERCEPHARMA
Oncology, RNA biotech 858 Therapeutics inks $60M series A
21 Sep 2021 //
FIERCEBIOTECH
HilleVax raises $135M and enlists an A-list board to advance late-stage vaccine
08 Sep 2021 //
ENDPTS
Biocon inks patent litigation settlement pact with Celgene
08 Sep 2021 //
ECONOMIC TIMES
Evotec announces BMS opt-in of EVT8683 from iPSC-based collaboration
04 Sep 2021 //
PHARMATIMES
Celgene Europe`s Abecma (idecabtagene vicleucel) Receives Approval in Europe
18 Aug 2021 //
EMA
Bristol-Myers Squibb and Nimbus involve in lawsuit over next-gen psoriasis drug.
17 Aug 2021 //
ENDPTS
BMS inks another Revlimid patent settlement—this time with Sun Pharma
23 Jun 2021 //
FIERCEPHARMA
BMS inks another Revlimid patent settlement—this time with Sun Pharma
22 Jun 2021 //
FIERCEPHARMA
It had to happen: Ex-Celgene shareholders sue BMS for $6B
04 Jun 2021 //
FIERCE PHARMA
Bristol Myers gets its first GI drug approval, & comes from a longtime Celgene
29 May 2021 //
ENDPTS
BMS is beefing up its cell therapy production network
23 Mar 2021 //
FIERCEPHARMA
Zydus settles Revlimid patent litigation with Celgene
23 Mar 2021 //
PHARMABIZ
BMS finally gets FDA OK for liso-cel, sets $410k launch price
09 Feb 2021 //
PHARMAPHORUM
Bristol Myers Squibb can grow through Revlimid generics, execs insist
06 Feb 2021 //
FIERCE PHARMA
BMY`s Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0B
04 Feb 2021 //
BUSINESSWIRE
Bristol Myers turns priority review for supplemental indication old Celgene drug
04 Feb 2021 //
ENDPTS
Bristol Myers Gains Covid Antibody in Deal With Rockefeller (Bloomberg)
03 Feb 2021 //
BLOOMBERG
Celgene`s cell therapy spinout nets $292M from blank-check merger
09 Jan 2021 //
BIOPHARMADIVE
How an all-or-nothing bet on 3 Bristol Myers drugs came undone
04 Jan 2021 //
BIOPHARMADIVE
Celgene, Cipla Resolve Patent Claims Over Cancer Drug
14 Dec 2020 //
LAW360
Bristol CVR up on hopes of FDA inspection for delayed CAR-T drug
05 Dec 2020 //
FIERCE PHARMA
Renegotiate the $6B CVR deal Bristol Myers made for the Celgene buyout?
19 Nov 2020 //
ENDPTS
Bristol Myers` $9 Celgene CVR is teetering on the brink of disaster as the FDA
17 Nov 2020 //
ENDPTS
FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs
16 Nov 2020 //
REUTERS
Bristol Myers hints at some problems with an FDA inspection needed liso-cel OK
06 Nov 2020 //
ENDPTS
Amgen`s Otezla faces a hit from Bristol`s would-be rival, but safety data
04 Nov 2020 //
FIERCE PHARMA
Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge
02 Nov 2020 //
BIOPHARMADIVE
Mesoblast stumble weighs on Celgene CVR
02 Oct 2020 //
SEEKINGALFA
